BioSpace News Archive

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in Citi’s 15 th Annual Virtual BioPharma Conference, September 9-10, 2020. Bruce Goldsmith, Ph.D., president and chief executive officer, will participate in a panel entitled “Disease Modifying Therapies of Neurodegenerative Diseases”

Neumentum Inc. , a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that may have the potential to replace opioids, at PAINWeek 2020 Live Virtual Conference, being held on September 11-13, 2020. The following poster presentations will be available on the PAINWeek 2020 website:

Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today announced that management will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Conference. Itamar’s management is scheduled to present on Wednesday, September 16, 2020 a

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that its management team will participate in the following September virtual investor conferences: Citi 15 th Annual BioPharma Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer & Co. Fall Healthcare Life Sciences &

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright & Co. 22 nd Annual Global Investment Conference 2020 Wednesday, September 16, 2020 Presentation time:

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced sales for the month of August 2020 were $1,190,000. This compares with sales for the month of July 2020 of $550,000, with growth driven by week

- Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine) tablets, Rebif® (interferon beta-1a) and investigational evobrutinib - New data and real-world evidence further characterize the efficacy and safety profiles of MAVENCLAD® - New MAVENCLAD® and Rebif® safety data to be shared regarding risk of respiratory viral infections

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following upcoming virtual investor conferences in September: Citi 15 th Annual BioPharma Virtual Conference 2020 on Wednesday, September 9 and Thursday, September 10, 2020, IVERIC bio will host meetings with investors. Cantor Virtual Global Healthcare Conference 2020 on Wednesday, September 16, 2020 at 8:00 a.m. E

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that management will participate in two upcoming investor conferences. John Tucker, Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright